GeneNews Debentureholders Approve Amendment To Convertible Debentures

Published: Dec 06, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

TORONTO, Dec. 5, 2013 (GLOBE NEWSWIRE) -- GeneNews Limited ("GeneNews" or the "Company") (TSX:GEN) announced today that, further to its press release of November 13, 2013, it has received the requisite approval of the holders of outstanding convertible debentures of the Company (the "Convertible Debentures") to an amendment to the Convertible Debentures pursuant to which holders of the Convertible Debentures may convert the principal amount of their Convertible Debentures (the "Conversion Opportunity"), together with accrued and unpaid interest thereon, into common shares of the Company ("Common Shares") as of December 18, 2013, at a price per Common Share equal to 90% of the five (5) day volume weighted average price of the Common Shares on the Toronto Stock Exchange (the "TSX") for the period ending on December 11, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news